Crinetics Pharmaceuticals

Summary

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

History

Crinetics Pharmaceuticals was founded in 2010 by Scientists of The Scripps Research Institute and is headquarters in San Diego, California. The company's focus lies in the creation of therapies and treatments for rare endocrine diseases and endocrine-related tumors.

Mission

Our mission is to transform the lives of patients through innovative and rigorous drug discovery, development, and commercialization.

Vision

Our vision is to become the global leader in developing and delivering therapeutic solutions for rare endocrine diseases and endocrine-related tumors.

References

https://in.investing.com/equities/crinetics-pharmaceuticals-inc

https://finance.yahoo.com/quote/CRNX/profile?p=CRNX

https://www.crunchbase.com/organization/crinetics-pharmaceuticals

https://sec.report/CIK/0001658247

https://companiesmarketcap.com/

https://www.crinetics.com

Contacts

Follow Us

Crinetics Pharmaceuticals

Share

Contacts

Follow Us